GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Gain Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.25−0.01 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $53.60M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.62 (−33.16%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $53.60M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.75
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$20.11M
- EPS, diluted
- -$0.51
- Book value per share
- $0.26
- Diluted shares
- 43M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$19.29M
Net income
-$20.11M
EPS, diluted
-$0.51
Free cash flow
–
Reported periodTrailing twelve months